REGENXBIO Inc — Quarterly Cash Flow (NASDAQ:RGNX) | MetaTrader

Open full chart

Financials

Overview Finanzbericht Statistics Dividends

Quarterly Annual

Total assets 519.11 M465.99 M490.93 M581.03 M525.2 M Total liabilities 217.7 M206.34 M216.73 M367.35 M363.75 M Total equity 301.42 M259.65 M274.2 M213.68 M161.45 M Total liabilities & shareholders' equities 519.11 M465.99 M490.93 M581.03 M525.2 M Total debt ————— Net debt —————

Nachrichten

Stifel bewertet uniQure nach Äußerungen des FDA-Commissioners zu seltenen Krankheiten

Stifel comments on uniQure shares after FDA commissioner remarks

Uniqure Plummets As FDA's Marty Makary Disparages Rejected Rare Disease Drug

Regenxbio (RGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Is the SPDR S&P Biotech ETF (XBI) a ‘Strong Buy’ Right Now? - TipRanks.com

REGENXBIO: Cautiously Bullish After FDA Setbacks (NASDAQ:RGNX)

Regenxbio: H.C. Wainwright senkt Kursziel nach FDA-Ablehnung auf 32 US-Dollar

Regenxbio stock price target lowered to $32 at H.C. Wainwright after FDA rejection

Intel, Wells Fargo among market cap stock movers on Tuesday

Netflix and Oracle among market cap stock movers on Tuesday

Regenxbio: Goldman Sachs senkt Kursziel nach Rückschlag bei RGX-121

Regenxbio stock price target lowered by Goldman Sachs on RGX-121 setback